Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

被引：0

作者：

Liu, Wei ^{[1
]}

Wang, Yi ^{[1
]}

Xu, Yan ^{[1
]}

Du, Chenxing ^{[1
]}

Wang, Qi ^{[1
]}

Wang, Tingyu ^{[1
]}

Huang, Wenyang ^{[1
]}

Zhang, Shuaishuai ^{[1
]}

Yi, Shuhua ^{[1
]}

Yan, Yuting ^{[1
]}

Yu, Tengteng ^{[1
]}

Sui, Weiwei ^{[1
]}

An, Gang ^{[1
]}

Lyu, Rui ^{[1
]}

Liu, Huimin ^{[1
]}

Xiong, Wenjie ^{[1
]}

Fu, Mingwei ^{[1
]}

Zou, Dehui ^{[1
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185669

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Younes, A
Preti, HA
Hagemeister, FB
McLaughlin, P
Romaguera, JE
Rodriguez, MA
Samuels, BI
Palmer, JL
Cabanillas, F
ANNALS OF ONCOLOGY, 2001, 12 (07) : 923 - 927
[22] Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
Georgiev, P. G.
Belada, D.
Dakhil, S.
Inhorn, L. F.
Andorsky, D.
Liberati, A. M.
Beck, J. T.
Quick, D.
Patti, C.
Sivcheva, L.
Zaucha, J. M.
Pettengell, R.
Devries, T.
Dean, J. P.
Pavlyuk, M.
Failloux, N.
Huebel, K.
ANNALS OF ONCOLOGY, 2016, 27
[23] Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma
不详
EUROPEAN JOURNAL OF CANCER CARE, 2003, 12 (04) : 306 - 307
[24] Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma
Yau, JC
Germond, C
Gluck, S
Cripps, C
Verma, S
Burns, BF
Koski, TN
Lister, DC
Goss, GD
AMERICAN JOURNAL OF HEMATOLOGY, 1998, 59 (02) : 156 - 160
[25] Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma
Aydin, Muruvvet Seda
Cengiz, Esra
Can, Ferda
Dagdas, Simten
Dilek, Imdat
Ozet, Gulsum
BLOOD RESEARCH, 2023, 58 (04) : 234 - 237
[26] Fludarabine, mitoxantrone and dexamethasone in the treatment of relapsed and refractory lowgrade non-Hodgkin lymphoma
Sawczuk-Chabin, J
Kalinka, E
Centkowski, P
Budziszewska, K
Ceglarek, B
Najda, J
Blasinska-Morawiec, M
Sulek, K
Holowiecki, J
Konopka, L
Warzocha, K
ANNALS OF ONCOLOGY, 2005, 16 : 151 - 151
[27] Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Canales, MA
Sanjurjo, MJ
Garcia-Vela, JA
de Paz, R
Gracia, J
Hernandez, D
Bustos, JG
Hernandez-Navarro, F
BLOOD, 2003, 102 (11) : 289B - 289B
[28] Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma in the post-transplant setting.
Pan, D
Moskowitz, CH
Zelenetz, AD
Teruya-Feldstein, J
Portlock, CS
BLOOD, 2000, 96 (11) : 405A - 405A
[29] Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Venugopal, P
Gretory, SA
Showel, J
Shammo, J
Enschede, S
Larson, M
Obrien, T
Sokolovsky, TD
Means, A
BLOOD, 2004, 104 (11) : 243B - 243B
[30] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
Leonard, JP
Coleman, M
Ketas, J
Ashe, M
Fiore, JM
Furman, RR
Niesvizky, R
Shore, T
Chadburn, A
Horne, H
Kovacs, J
Ding, CL
Wegener, WA
Horak, ID
Goldenberg, DM
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5044 - 5051

← 1 2 3 4 5 →